Cleveland BioLabs Stock Price - CBLI

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Cleveland BioLabs Inc CBLI NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.01948 -2.95% 0.64 0.64 0.64 0.64 0.659475 09:30:00
Bid Price Ask Price Spread Spread % News
0.62 0.66 0.04 6.06% - -
Stock Trades Traded Volume Average Volume 52 Week Range
2 10 16,015 0.62 - 2.17
Last Trade Time Type Quantity Stock Price Currency
09:30:00 10 $ 0.64 USD

Cleveland BioLabs Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 7.45M 11.30M $ -3.61M -0.33 - 7.64M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Cleveland BioLabs News

Loading Messages....

Latest CBLI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CBLI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.680.690.620.64513354,631-0.04-5.88%
1 Month0.97650.97650.620.786893520,169-0.3365-34.46%
3 Months1.42751.5180.620.985182715,356-0.7875-55.17%
6 Months1.631.700.621.139,640-0.99-60.74%
1 Year1.712.170.621.4113,519-1.07-62.57%
3 Years1.55665.550.624.09138,519-0.9166-58.88%
5 Years0.38017.240.193.79147,1710.259968.38%

Cleveland BioLabs Description

Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and an immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.